Skip to content

Study on the Effect of Intracoronary Thrombolysis with Recombinant Human Pro-urokinase (rhPro-UK) on TIMI Flow and Prognosis in STEMI Patients (PUK-ICT)

Study on the Effect of Intracoronary Thrombolysis with Recombinant Human Pro-urokinase (rhPro-UK) on TIMI Flow and Prognosis in STEMI Patients (PUK-ICT)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500105815
Enrollment
Unknown
Registered
2025-07-11
Start date
2025-10-16
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute ST-segment elevation myocardial infarction

Interventions

Intervention group:20mg rhPro-UK was injected into the coronary artery
control group:10ml of normal saline was injected into the coronary artery

Sponsors

The First Hospital of Lanzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.18-75 years old; 2.STEMI=3(TIMI blood flow grade 2-3); 5.There are indications for interventional therapy; 6.Patients and their families understand the purpose and procedures of this study, voluntarily participate in this study, sign written informed consent, and are able to follow the research plan and other protocol requirements.

Exclusion criteria

Exclusion criteria: 1.STEMI>12 h; 2.TIMI thrombosis grade <3; 3.Intra-arterial thrombolysis has restored TIMI-3 grade blood flow; 4.Cardiac arrest or shock state before interventional surgery, requiring mechanical assistance; 5.Left main trunk lesion; 6.Coronary artery bridge occlusion; 7.the criminal's blood vessels have previously suffered from infarction; 8.Occluded lesions are located in the coronary artery branches; 9.Poor image quality, unable to perform QFR, cTFC, MBG analysis; 10.Women of childbearing age who are pregnant or planning to become pregnant; 11.Life expectancy is less than one year; 12.Participate in any other drug, device or biologic clinical trial currently or expected to be conducted during the study period; 13.Severe liver or kidney dysfunction; 14.Poor compliance, unable to review and follow up on time.

Design outcomes

Primary

MeasureTime frame
MACE events (all-cause death, cardiovascular death, readmission for heart failure, target vessel-related AMI, Shock) at 9 months postintervention;Bleeding with perioperative BARC >=3;

Secondary

MeasureTime frame
TIMI blood flow grade and TIMI blood flow frame count (cTFC, MBG, TMPG) immediately after interventional surgery;The proportion of STR>50% within 90min after interventional surgery;LVEF values and WMSI within 24 hours after interventional surgery;LVEF values and WMS at 3 months postintervention;

Countries

China

Contacts

Public ContactZheng Zhang

The First Hospital of Lanzhou University

zhangccu@163.com+86 139 1940 5976

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026